<SEC-DOCUMENT>0001213900-24-045159.txt : 20240520
<SEC-HEADER>0001213900-24-045159.hdr.sgml : 20240520
<ACCEPTANCE-DATETIME>20240520160200
ACCESSION NUMBER:		0001213900-24-045159
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240520
DATE AS OF CHANGE:		20240520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279276
		FILM NUMBER:		24964305

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea0206537-f1a1_inspira.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM F-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As filed with the Securities and Exchange
Commission&nbsp;on May 20, 2024</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Registration No. 333-279276</B> </P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>AMENDMENT NO. 1 TO</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of registrant as specified in its
charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>State&nbsp;of&nbsp;Israel</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>3841</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Not&nbsp;Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</I></FONT><BR>
    <FONT STYLE="font-size: 10pt"><I>incorporation&nbsp;or&nbsp;organization)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(Primary&nbsp;Standard&nbsp;Industrial</I></FONT><BR>
    <FONT STYLE="font-size: 10pt"><I>Classification&nbsp;Code&nbsp;Number)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(I.R.S.&nbsp;Employer</I></FONT><BR>
    <FONT STYLE="font-size: 10pt"><I>Identification&nbsp;Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Ha-Tidhar St.,</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ra&rsquo;anana, 4366504 Israel</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: +972.4.6230333</B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-bottom: 1.5pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Puglisi &amp; Associates</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>850 Library Ave., Suite 204</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newark, DE 19711</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (302) 738-6680</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(Address, including zip
    code, and telephone number,</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(Name, address, including
    zip code, and telephone</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>including area code, of
    registrant&rsquo;s principal executive offices)</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>number, including area
    code, of agent for service)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oded
    Har-Even, Esq.<BR>
    Ron Ben-Bassat, Esq.<BR>
    Angela Gomes, Esq.</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reut
    Alfiah, Adv.<BR>
    Gal Cohen, Adv.<BR>
    Sullivan &amp; Worcester Tel-Aviv</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sullivan &amp; Worcester
    LLP<BR>
    1251 Avenue of the Americas, 19<SUP>th</SUP> Floor<BR>
    New York, NY 10020<BR>
    Tel: 212.660.3000</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Har-Even
    &amp; Co.)<BR>
    28 HaArba&rsquo;a St. HaArba&rsquo;a<BR>
    Towers,<BR>
    North Tower, 35<SUP>th</SUP> Floor<BR>
    Tel-Aviv, Israel 6473925<BR>
    T&nbsp;+972.74.758.0480</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed
sale to the public:</B> As soon as practicable after the effective date hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on
this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act, check the following
box.&nbsp;&#9746;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed
pursuant to Rule&nbsp;462&copy; under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering.&nbsp;&#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed
pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering.&nbsp; &#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;&#9746;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards &dagger; provided pursuant to Section 7(a)(2)(B) of the Securities
Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&dagger;</TD><TD STYLE="text-align: justify">The term &ldquo;new
                                            or revised financial accounting standard&rdquo; refers to any update issued by the Financial
                                            Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities
Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a),
may determine.</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>DATED:
    MAY 20, 2024</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 4,416,916 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the offer and resale
by the selling shareholders identified in this prospectus, or the Selling Shareholders, of up to an aggregate of 953,478 ordinary shares,
no par value, or the Ordinary Shares, of Inspira Technologies Oxy B.H.N. Ltd., issued to certain Selling Shareholders, or the Resale
Ordinary Shares, and up to 3,463,438 Ordinary Shares issuable upon exercise of certain outstanding warrants issued to certain Selling
Shareholders at exercise prices between $1.28 and $2.25 per share, or the Warrants, and the Ordinary Shares underlying the Warrants,
the Warrant Shares and together with the Resale Ordinary Shares, the Resale Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Resale Shares will be resold from time to
time by the Selling Shareholders listed in the section titled &ldquo;Selling Shareholders&rdquo; beginning on page 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Selling Shareholders, or their respective
transferees, pledgees, donees or other successors-in-interest, may sell the Resale Shares through public or private transactions at prevailing
market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Shareholders may sell any,
all or none of the securities offered by this prospectus, and we do not know when or in what amount the Selling Shareholders may sell
their Resale Shares hereunder following the effective date of the registration statement of this prospectus forms a part. We provide
more information about how a Selling Shareholders may sell its Warrant Shares in the section titled &ldquo;Plan of Distribution&rdquo;
on page 10. The Selling Shareholders and any broker-dealer participating in the distribution of the Ordinary Shares may be deemed to
be &ldquo;underwriters&rdquo; within the meaning of the U.S. Securities Act of 1933, as amended, or the Securities Act, and any commission
paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under
the Securities Act. At the time a particular offering of the Ordinary Shares is made, a prospectus supplement, if required, will be distributed
which will set forth the aggregate amount of Ordinary Shares being offered and the terms of the offering, including the name or names
of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the Selling Shareholders and
any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering the Resale Shares on behalf
of the Selling Shareholders, to be offered and sold by it from time to time. While we will not receive any proceeds from the sale of
any Resale Shares by the Selling Shareholders described in this prospectus, we will receive between $1.28 and $2.25 per Warrant Share
to the extent that the Warrants are exercised for cash. Upon exercise of the Warrants for all 3,463,438 Warrant Shares by payment of
cash, we will receive aggregate gross proceeds of approximately $4.7 million. However, we cannot predict when and in what amounts or
if the Warrants will be exercised, and it is possible that the Warrants may expire and never be exercised, in which case we would not
receive any cash proceeds. We have agreed to bear all of the expenses incurred in connection with the registration of the Resale Shares.
The Selling Shareholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar
expenses, if any, incurred for the sale of the Resale Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our Ordinary Shares and warrants to purchase
Ordinary Shares issued in our initial public offering, or the IPO Warrants, are listed on the Nasdaq Capital Market, or Nasdaq, under
the symbols &ldquo;IINN&rdquo; and &ldquo;IINNW&rdquo;, respectively. On May 17, 2024, the last reported sale price of our Ordinary Shares
and IPO Warrants on Nasdaq was $2.30 and $0.55, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We are an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and a &ldquo;foreign private issuer&rdquo;, as defined in Rule 405
under the Securities Act, and are eligible for reduced public company reporting requirements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk.&nbsp;You should read the &ldquo;Risk Factors&rdquo; section starting on page 4 of this prospectus and in our Annual Report
on Form 20-F for the fiscal year ended December 31, 2023, which is incorporated by reference into this prospectus, for a discussion of
factors to consider carefully before deciding to invest in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the SEC nor any state or other foreign
securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete.&nbsp;Any
representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">ii</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003">THE OFFERING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004">RISK FACTORS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">4</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">5</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">SELLING SHAREHOLDERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">7</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">10</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">12</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">13</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010">CAPITALIZATION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">14</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011">EXPENSES</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_015">ENFORCEABILITY OF CIVIL LIABILITIES</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">16</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">17</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>You
should rely only on the information contained in this prospectus or any amendment thereto prepared by or on behalf of us or to which
we have referred you. We have not authorized anyone to provide you with information that is different. We are offering to sell our securities,
and seeking offers to buy our securities, only in jurisdictions where offers and sales are permitted. The information in this prospectus
is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United
States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Inspira&rdquo; refer to
Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this prospectus are referred to without the &reg; and &trade; symbols, but such references should not be construed
as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
reporting currency is the U.S. dollar and our functional currency is New Israeli Shekels.&nbsp;Unless otherwise expressly stated or the
context otherwise requires, references in this prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, references to A$ are to Australian
dollars, and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are to U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent
industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports
generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy
or completeness of the information. Although we believe that these sources are reliable, we have not independently verified the information
contained in such publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the
IASB.&nbsp;None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus describes
the general manner in which the Selling Shareholders may offer from time to time up to 953,478 Resale Ordinary Shares and 3,463,438 Warrant
Shares. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus or amendment thereto
and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor
the Selling Shareholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. This prospectus, any prospectus or amendments thereto do not constitute an offer to sell, or
a solicitation of an offer to purchase, the Resale Shares offered by this prospectus, any prospectus or amendments thereto in any jurisdiction
to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should
not assume that the information contained in this prospectus, any prospectus or amendments thereto, as well as information we have previously
filed with the SEC is accurate as of any date other than the date on the front cover of the applicable document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If necessary, the specific
manner in which the Resale Shares may be offered and sold will be described in a supplement to this prospectus, which supplement may
also add, update or change any of the information contained in this prospectus. To the extent there is a conflict between the information
contained in this prospectus, you should rely on the information in such prospectus, provided that if any statement in one of these documents
is inconsistent with a statement in another document having a later date &mdash; for example, a document incorporated by reference in
this prospectus&mdash; the statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the delivery of this
prospectus nor any distribution of Resale Shares pursuant to this prospectus shall, under any circumstances, create any implication that
there has been no change in the information set forth or incorporated by reference into this prospectus or in our affairs since the date
of this prospectus. Our business, financial condition, results of operations and prospects may have changed since such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing
in our Ordinary Shares. Before you decide to invest in our Ordinary Shares, you should read the entire prospectus carefully, including
the &ldquo;Risk Factors&rdquo; section, and the financial statements and related notes thereto and the other information incorporated
by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary life support technology with a vision
to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of
acute respiratory failure. Although it may be sometimes lifesaving, Mechanical Ventilation is associated with increased risks, costs
of care, extended lengths of stay, frequent incidence of infections, ventilator dependence and mortality. Using our state-of-the-art
life support technology, our goal is to set a new standard of care and to provide patients with acute respiratory failure an opportunity
to maintain spontaneous breathing and avoid the need for intubation, coma and various risks associated with the use of Mechanical Ventilation.
As part of our strategy to reach this goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations
with strategic partners, globally ranked hospitals, medical device companies and distributors both for endorsement and early clinical
adoption. We plan to target intensive care units, or ICUs, general medical units, operating theaters, and small urban and rural hospitals,
with the goal of making our solutions more accessible to millions of patients worldwide. We expect for these activities to support our
strategy plan to reach market penetration and adoption of our life support technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing the following
products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The INSPIRA<SUP>TM</SUP>
ART </B>(Gen 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART device (Augmented
Respiratory Technology) (also known as the INSPIRA ART500, ART system or ART), described herein as the INSPIRA ART, INSPIRA ART (Gen2),
INSPIRA ART device or INSPIRA ART system, our flagship product, is a life support technology targeting to utilize direct blood oxygenation
to boost patient saturation levels within minutes while the patient is awake &amp; spontaneously breathing. It is designed to perform
Adaptive Blood Oxygenation, by continuously measuring the patient&rsquo;s blood parameters in real-time, delivering needed oxygen volume
straight into the blood. The aim of our products is to treat patients without the need for Mechanical Ventilation with the potential
to reduce associated legacy risks, complications and high costs and potentially allowing for treatment of larger patient populations
in and beyond ICU settings. The INSPIRA ART is being designed as a new intent of use for long-term (longer than 6 hours) life support
that provides assisted extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient&rsquo;s blood
in adults with acute respiratory failure, targeting to allow for treatment of patients while they are awake. The INSPIRA ART is being
designed to potentially prevent the need for invasive mechanical ventilation, targeting acute respiratory failure patients in ICUs and
general medical units. The break-through INSPIRA ART, which is still in development and has not been tested or used on humans and is
expected to be submitted to the U.S. Food and Drug Administration, or FDA, for regulatory approval via the pre-market approval application
or De Novo regulatory pathways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The INSPIRA<SUP>TM</SUP>
ART100 (Gen 1)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 device
(previously referred to as the ALICE, Liby or ECLS system), described herein as the INSPIRA ART100 (Gen 1), INSPIRA ART100, or the INSPIRA
ART100 device, an advanced form of life support system better known by the medical industry as a cardiopulmonary bypass system, or CPB,
is being designed for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or less. The INSPIRA ART100 device was
submitted to the FDA for 510k clearance in September 2023, and we expect a response by the end of the first half of 2024. The INSPIRA
ART100 is designed to be a new generation CPB system with potential advantages to medical device design with ergonomic configuration
and intuitive user-centric software and display to increase functionality, as well as a large touchscreen with novel colorful graphical
representation that increases the visibility and functionality of data displayed to the medical staff. The INSPIRA ART100 device is being
designed to be lightweight and highly durable and will be equipped with long battery life to maximize its portability. The INSPIRA ART100
device, designed as a CPB, shall be indicated for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or less. The
device is designed to be versatile, working with certain disposables manufactured by leading market players in the space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The HYLA<SUP>TM</SUP>
Blood Sensor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor, described
herein as the HYLA or HYLA blood sensor, originally designed as a key and core technology for the INSPIRA ART (Gen 2), is being developed
in its first variant (HYLA 1) to be compatible with the INSPIRA ART100 with plans to also be a stand-alone device to be integrated or
used in extracorporeal procedures. The HYLA is designed as a non-invasive optical blood sensor designed to perform real-time and continuous
blood measurements, to potentially alert physicians of changes in patient&rsquo;s clinical condition. The HYLA blood sensor is being
designed as a clip-on sensor, attached to the outer walls of a blood tube, that may potentially reduce risks, complications, and costs.
The HYLA blood sensor may have broad application potential, benefiting patients undergoing procedures such as cardiopulmonary bypass
operations, Extracorporeal Membrane Oxygenation, or ECMO and Cardiopulmonary bypass, pending regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a goal to set a new
standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel to pursuing regulatory
approvals, we are actively working to establish collaborations with strategic partners and globally ranked health centers to provide
endorsement and clinical adoption for regional deployments of our products and technologies. We plan to target ICUs, general medical
units, Operating theaters, and small urban and rural hospitals, with the goal of making our solutions more accessible to millions of
patients.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We are an Israeli corporation
based in Ra&rsquo;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira Technologies Oxy B.H.N. Ltd.
Our principal executive offices are located at 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel. Our telephone number in Israel is 972
996 644 88. Our website address is&nbsp;<I>www.inspira-technologies.com</I>. The information contained on, or that can be accessed through,
our website is not part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; background-color: white"><B>Implications of Being an Emerging
Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified
by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements
applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; such as not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We could remain an
&ldquo;emerging growth company&rdquo; for up to five years, or until the earliest of (a)&nbsp;the last day of the first fiscal year in
which our annual gross revenues exceeds $1.235&nbsp;billion, (b)&nbsp;the date that we become a &ldquo;large accelerated filer&rdquo;
as defined in Rule&nbsp;12b-2 under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the
market value of our Ordinary Shares that are held by non-affiliates exceeds $700&nbsp;million as of the last business day of our most
recently completed second fiscal quarter, or (c)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt
during the preceding three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of being a &ldquo;Foreign Private
Issuer&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act that are applicable to &ldquo;foreign private issuers,&rdquo; and under those requirements,
we file reports with the SEC. As a foreign private issuer, we are not subject to the same requirements that are imposed upon U.S. domestic
issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and
less frequent than those of U.S. domestic reporting companies. For example, we are not required to issue quarterly reports, proxy statements
that comply with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that
is as detailed as that required of U.S. domestic reporting companies. We also have four months after the end of each fiscal year to file
our annual report with the SEC and are not required to file current reports as frequently or promptly as U.S. domestic reporting companies.
Our officers, directors, and principal shareholders are exempt from the requirements to report transactions in our equity securities
and from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign private issuer, we are
not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition, as a foreign private
issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the
Nasdaq Stock Market rules for domestic U.S. issuers and are not required to be compliant with all Nasdaq Stock Market rules as would
domestic U.S. issuers. See &ldquo;<I>Risk Factors&mdash;Risks Related to the Offering and Ownership of our Securities</I>&rdquo; for
additional information. These exemptions and leniencies will reduce the frequency and scope of information and protections available
to you in comparison to those applicable to a U.S. domestic reporting company. We intend to take advantage of the exemptions available
to us as a foreign private issuer during and after the period we qualify as an &ldquo;emerging growth company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recent Developments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, we issued
and sold in a registered direct offering an aggregate of 1,339,285 Ordinary Shares to certain investors at a purchase price of $1.232
per share for aggregate gross proceeds to the Company of $1.65 million pursuant to a definitive agreement, dated March 28, 2024, with
such investors (the &ldquo;March Registered Direct Offering&rdquo;). Our Chief Executive Officer&rsquo;s mother purchased 324,675 Ordinary
Shares in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares currently issued and outstanding</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 63%; padding-right: 0.8pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> 17,375,042&nbsp;Ordinary
                                            Shares </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Resale Shares offered by the Selling Shareholders</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Up to 4,416,916 Ordinary Shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt"><B>Ordinary Shares to be outstanding after this offering (assuming full exercise of the Warrants
    that are exercisable for the Warrant Shares offered hereby):</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> 20,838,480
                                            Ordinary Shares. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will not receive any of the proceeds from any sale of any Resale
    Shares by the Selling Shareholders. We may receive proceeds in the event that any of the Warrants are exercised at their respective
    exercise prices per share which may result in gross proceeds of approximately $4.7 million, if all of the Warrants are exercised
    for cash. Any proceeds that we receive from the exercise of the Warrants will be used for working capital and other general corporate
    purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 63%; text-align: justify"><FONT STYLE="font-size: 10pt">You should read the &ldquo;Risk Factors&rdquo; section
    starting on page 4 of this prospectus and in our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which is
    incorporated by reference into this prospectus, for a discussion of factors to consider carefully before deciding to invest in our
    securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Nasdaq symbol</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 63%; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;IINN&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Unless otherwise indicated,
the number of Ordinary Shares outstanding prior to and after this offering is based on 17,375,042 Ordinary Shares outstanding as of May
17, 2024, and excludes the following as of such date: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">542,800
                                            Ordinary Shares issuable upon the exercise of options to directors, employees and consultants
                                            under our equity incentive plan, outstanding as of such date, with exercise prices ranging
                                            between NIS 0.37 (approximately $0.11) to NIS 0.97 (approximately $0.29) per share, 29,400
                                            Ordinary Shares issuable upon the exercise of options to consultants under our equity incentive
                                            plan, outstanding as of such date, with exercise price of $3.08 and 80,000 Ordinary Shares
                                            issuable upon the exercise of options to consultants under our equity incentive plan, outstanding
                                            as of such date, with exercise price of $1.002(approximately $0.28); 501,968 of the total
                                            options were vested as of such date;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,659,742
    Restricted Share Units, or RSUs, granted to directors, employees, and consultants under our equity incentive plan, none of which
    were vested as of such date;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">326,921 Ordinary Shares reserved for future issuance under our equity
    incentive plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">169,016 Ordinary Shares issuable upon the exercise of warrants issued
    to InSense Medical Pty Ltd. in connection with a certain termination agreement, at an exercise price of $5.50 per Ordinary Share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">795,832 Ordinary Shares issuable upon the exercise of warrants issued
    in connection with certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs,&nbsp;and
    an additional 3,247 Ordinary Shares issuable upon the exercise of warrants issued to promoters in connection with such SAFEs; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">353,750 Ordinary Shares issuable upon the exercise of warrants issued
    in connection with a certain convertible loan, and an additional 13,340 Ordinary Shares issuable upon the exercise of warrants issued
    to promoters in connection with such convertible loan agreements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">145,455 Ordinary Shares issuable upon the exercise of warrants issued
    to Aegis Capital Corp. who acted as our underwriter in connection with our initial public offering, or IPO, at an exercise price
    of $6.875 per share; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,640,455 Ordinary Shares issuable upon the exercise of our IPO Warrants
    at an exercise price of $5.50 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>
</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>An investment in the Ordinary
Shares involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties.
You should consider carefully the risk factors described below and the risks described under the caption &ldquo;Item 3. Key Information
- D. Risk Factors&rdquo; in our&nbsp;Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on March
25, 2024, which is incorporated by reference in this prospectus, before deciding whether to invest in the Ordinary Shares. The risks
described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem
to be immaterial may also materially and adversely affect our business operations. If any of these risks actually occur, our business,
financial condition, operating results or cash flows could be materially adversely affected. This could cause the trading price of the
Ordinary Shares to decline, and you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to this Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales of our Ordinary Shares could
reduce the market price of our securities.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantial sales of our
Ordinary Shares on Nasdaq may cause the market price of our securities to decline. Sales by us or our security holders of substantial
amounts of our Ordinary Shares, or the perception that these sales may occur in the future, could cause a reduction in the market price
of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of any additional
Ordinary Shares or any securities that are exercisable for or convertible into Ordinary Shares, may have an adverse effect on the market
price of our Ordinary Shares and will have a dilutive effect on our existing shareholders and holders of Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience future dilution as a
result of future equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we may in the future offer additional Ordinary Shares or other securities convertible into or exchangeable for Ordinary Shares
at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering
at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional Ordinary
Shares, or securities convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price
per share paid by investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may need additional financing in the
future. We may be unable to obtain additional financing or if we obtain financing it may not be on terms favorable to us. You may lose
your entire investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current plans,
we believe our existing cash and cash equivalents will be sufficient to fund our operating expense and capital requirements for the next
six months. We expect that we will require substantial additional capital to operate and to commercialize our products and we expect
to seek additional funds to enable us to fund our operations for the next twelve months. We may be unable to obtain additional funds
through financing activities, and if we obtain financing it may not be on terms favorable to us. If we are unable to obtain additional
funds on terms favorable to us, we may be required to cease or reduce our operating activities. If we must cease or reduce our operating
activities, you may lose your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of the Ordinary Shares may be
volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of the Ordinary
Shares has fluctuated in the past. Consequently, the current market price of the Ordinary Shares may not be indicative of future market
prices, and we may be unable to sustain or increase the value of your investment in the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in Ordinary Shares as a source for any future dividend income.&nbsp;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if
any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our
board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_005"></A>CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this prospectus may be deemed to be &ldquo;forward-looking statements&rdquo; within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal securities laws. &nbsp;Forward-looking statements are often characterized
by the use of forward-looking terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;believe,&rdquo; &ldquo;predict,&rdquo; &ldquo;should,&rdquo; &ldquo;intend,&rdquo;
&ldquo;project&rdquo; or other similar words, but are not the only way these statements are identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our planned level of revenues and capital expenditures;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our available cash our ability to obtain additional funding;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to market and sell our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectation regarding the sufficiency of our existing cash and
    cash equivalents to fund our current operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to advance the development of our products and future potential
    product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to commercialize our products and future potential product
    candidates and future sales of our products or any other future potential product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our assessment of the potential of our products and future potential
    product candidates to treat certain indications;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our planned level of capital expenditures and liquidity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our plans to continue to invest in research and development to develop
    technology for new products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to maintain our relationships with suppliers, manufacturers,
    distributors, and other partners;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">anticipated actions of the FDA, state regulators, if any, or other
    similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those trials and the
    prospects for regulatory approval or clearance of, or other regulatory action with respect to our products or services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the regulatory environment and changes in the health policies and regimes
    in the countries in which we intend to operate, including the impact of any changes in regulation and legislation that could affect
    the medical device industry;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to meet our expectations regarding the commercial supply
    of our products and future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to retain key office holders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to internally develop new inventions and intellectual property;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the overall global economic environment;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The possible impact of cybersecurity incidents on our business and
    operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general market, political and economic conditions in the countries
    in which we operate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to internally develop new inventions and intellectual property;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in our strategy; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">litigation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our
or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_006"></A>SELLING
SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Resale Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus covers the
resale of an aggregate of 953,478 Resale Ordinary Shares held by Dagi Ben-Noon, our Chief Executive Officer, and Joe Hayon, our President.
On February 19, 2018, we entered into an agreement, or the Founders Agreement, with Mr. Ben-Noon and other founders of the Company, pursuant
to which Mr. Ben-Noon was issued 23.94% of the then issued and outstanding share capital of the Company, or 626,739 Ordinary Shares (of
which 300,000 Ordinary Shares were transferred to Yael Ben-Noon on June 29, 2023). On May 10, 2016, we entered into an agreement, or
the Joinder to Founders Agreement, with Mr. Hayon, pursuant to which the Company issued to Mr. Hayon 23.94% of the then issued and outstanding
share capital of the Company, or 626,739 Ordinary Shares. On March 18, 2021, our shareholders approved a one-for-12.5 consolidation,
or a reverse split, of our Ordinary Shares pursuant to which holders of our Ordinary Shares received one Ordinary Share for every
12.5 Ordinary Shares held. On June 1, 2021, our shareholders approved an additional reverse split at a ratio of one-for-2.94, pursuant
to which holders of our Ordinary Shares received one Ordinary Share for every 2.94 Ordinary Shares held. All references to share and
per share amounts referred to with respect to Mr. Ben-Noon&rsquo;s and Mr. Hayon&rsquo;s Resale Ordinary Shares reflect the foregoing
reverse splits. We are registering the Resale Ordinary Shares in order to permit the Selling Shareholders to offer and sell the
Resale Ordinary Shares for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrant Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>December 2023 Concurrent Private Placement
Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus also covers the resale of up to 3,031,250 Armistice Warrant Shares (as defined below). On December 27, 2023, we entered into
a purchase agreement, or the Purchase Agreement, with Armistice Capital LLC, or Armistice, in a registered direct offering, pursuant
to which we issued (i) an aggregate of 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, and (ii) pre-funded warrants,
or the Pre-Funded Warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per Pre-Funded Warrant.
In addition, pursuant to the Purchase Agreement, and in a concurrent private placement, we issued to Armistice warrants, or the Armistice
Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share, or the Armistice Warrant Shares.
The Armistice Warrants were exercisable immediately upon issuance and expire three and a half years following their issuance. Each Pre-Funded
Warrant was exercisable for one Ordinary Share at an exercise price of $0.001 per share. The Pre-Funded Warrants were immediately exercisable
and have been fully exercised. We received aggregate gross proceeds of $3.88 million in the registered direct offering and concurrent
private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">H.C.
Wainwright &amp; Co., LLC, or the Placement Agent, acted as the exclusive placement agent for the registered direct offering and
concurrent private placement. We paid the Placement Agent an aggregate fee equal to 7.0% of the gross proceeds of the offering, a
management fee of 1.0% of the gross proceeds of the offering, a non-accountable expenses allowance of $85,000 and a clearing fee of
$15,950. In addition, on December 28, 2023, we issued to the Placement Agent&rsquo;s designees warrants to purchase up to an
aggregate of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, or warrants to purchase up to 212,188 Ordinary
Shares, or the Placement Agent Warrants and such shares, the Placement Agent Warrant Shares. The Placement Agent Warrants were
substantially on the same terms as the Armistice Warrants, except that the Placement Agent Warrants have an exercise price of $1.60
per share. The Placement Agent Warrants were issued to the four designees named herein: Charles Worthman, Craig Schwabe, Michael
Vasinkevich, and Noam Rubinstein. This prospectus also covers the resale of up to an aggregate of 212,188 Placement Agent Warrant
Shares issuable upon exercise of the Placement Agent Warrants held by Charles Worthman, Craig Schwabe, Michael Vasinkevich and Noam
Rubinstein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Service Provider Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus covers the
resale of up to 220,000 Warrant Shares issuable to a service provider, Talniri Ltd., or Talniri, upon the exercise of Warrants issued
to Talniri, in connection with a consulting agreement dated February 20, 2024. The Warrant Shares will become exercisable on May 20,
2024, or the Initial Exercise Date, at an exercise price of $2.25 per share and will expire six months following the Initial Exercise
Date, or on November 20, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the Resale
Shares to permit the Selling Shareholders to offer such shares for resale from time to time. This prospectus covers the resale of up
to an aggregate of 4,416,916 Resale Shares that may be sold or otherwise disposed of by the Selling Shareholders. Except for the ownership
of the Resale Ordinary Shares and Warrants and as disclosed in this section, the Selling Shareholders have no material relationship with
us within the past three years other than Dagi Ben-Noon, our Chief Executive Officer, and Joe Hayon, our President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The following table sets
forth certain information with respect to each Selling Shareholder, including (i) the Ordinary Shares beneficially owned by the Selling
Shareholder prior to this offering, (ii) the number of Resale Shares being offered by the Selling Shareholder pursuant to this prospectus
and (iii) the Selling Shareholder&rsquo;s beneficial ownership after completion of this offering assuming all Resale Shares are sold.
The registration of the Resale Shares does not necessarily mean that such Selling Shareholder will sell all or any of such shares, but
the number of Ordinary Shares and percentages set forth in the final two columns below assume that all of the Resale Shares being offered
by such Selling Shareholder are sold. The final two columns also assume the exercise of all of the Warrants held by such Selling Shareholder
as of May 17, 2024. See &ldquo;Plan of Distribution.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table is based on information
supplied to us by the Selling Shareholders, with beneficial ownership and percentage ownership determined in accordance with the rules
and regulations of the SEC, and includes voting or investment power with respect to our Ordinary Shares. This information does not necessarily
indicate beneficial ownership for any other purpose. In computing the number of Ordinary Shares beneficially owned by a Selling Shareholder
and the percentage ownership of that Selling Shareholder, Ordinary Shares subject to options and warrants held by that Selling Shareholder
that are exercisable for Ordinary Shares within 60 days after May 07, 2024, are deemed outstanding. Such shares, however, are not deemed
outstanding for the purposes of computing the percentage ownership of any other shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of<BR>
Ordinary Shares<BR>
Beneficially Owned<BR>
Prior to<BR>
Offering<SUP>(1)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum<BR>
Number of<BR>
Resale Shares<BR>
to be Sold<BR>
Pursuant to this Prospectus<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of<BR>
Ordinary Shares <BR>
Beneficially Owned After<BR>
Offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage<BR>
Beneficially<BR>
Owned After<BR>
Offering<SUP>(3)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital LLC</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,031,250</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,031,250</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(6)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles Worthman</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,122</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,122</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)(8)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig Schwabe</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,161</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,161</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)(9)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,304,398 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,739</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">977,659</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(13)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.69</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,606,242</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">626,739</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">979,503</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(14)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Vasinkevich</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,066</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,066</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)(10)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Rubinstein</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,839</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,839</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)(11)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Talniri Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">220,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">220,000</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(12)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,374,078</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,416,916</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,957,162</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.39</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left"> (1) </TD><TD STYLE="text-align: justify"> Beneficial ownership
                                            is determined in accordance with SEC rules and generally includes voting or investment power
                                            with respect to securities. Ordinary Shares subject to options or warrants currently exercisable,
                                            or exercisable within 60 days of May 17, 2024 are counted as outstanding for computing the
                                            percentage of the Selling Shareholder holding such options or warrants but are not counted
                                            as outstanding for computing the percentage of any other Selling Shareholder. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Represents Ordinary Shares
                                            owned by the Selling Shareholder, including upon full exercise of the Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left"> (3) </TD><TD STYLE="text-align: justify"> The applicable percentage
                                            of beneficial ownership is based on 20,838,480 Ordinary Shares issued and outstanding immediately
                                            after this offering (assuming the exercise of all Warrants). The calculation of beneficial
                                            ownership reported in such columns takes into account the effect of the beneficial ownership
                                            limitations in any warrants held by the Selling Shareholders after this offering. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Consists of (i) 326,739
                                            Ordinary Shares, (ii) 920,500 Ordinary Shares vested pursuant to issued and outstanding RSUs
                                            and (iii) 57,159 Ordinary Shares issuable upon the exercise of options within 60 days.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) 626,739 Ordinary Shares, (ii) 920,500 Ordinary Shares vested pursuant to issued and outstanding RSUs, and (iii) 57,159 Ordinary Shares issuable upon the exercise of options within 60 days.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.3in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Consists of 3,031,250
                                            Ordinary Shares issuable upon the exercise of the Armistice Warrants. Mr. Steven Boyd has
                                            dispositive power over the Warrant Shares held by Armistice Capital LLC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Selling Shareholder is affiliated with H.C. Wainwright &amp; Co., LLC, a registered broker dealer with a registered address of c/o
    H.C. Wainwright &amp; Co., 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the
    securities held. The number of Placement Agent Warrant Shares to be sold in this offering consists of Ordinary Shares issuable upon
    exercise of the Placement Agent Warrants, which were received as compensation for our registered direct offering consummated in
    December 2023. The Selling Shareholders acquired the Placement Agent Warrants in the ordinary course of business and, at the time
    the Placement Agent Warrants were acquired, the Selling Shareholders had no agreement or understanding, directly or indirectly, with
    any person to distribute such securities. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Consists of 2,122 Ordinary
                                            Shares issuable upon the exercise of Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(9)</TD><TD STYLE="text-align: justify">Consists of 7,161 Ordinary
                                            Shares issuable upon the exercise of Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(10)</TD><TD STYLE="text-align: justify">Consists of 136,066 Ordinary
                                            Shares issuable upon the exercise of Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(11)</TD><TD STYLE="text-align: justify">Consists of 66,839 Ordinary
                                            Shares issuable upon the exercise of Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(12)</TD><TD STYLE="text-align: justify">Consists of 220,000
                                            Ordinary Shares issuable upon the exercise of Warrants. Eldar Edmond Grady has sole dispositive
                                            power over the Warrant Shares held by Talniri Ltd.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(13)</TD><TD STYLE="text-align: justify">Consists of (i) 920,500
                                            Ordinary Shares vested pursuant to issued and outstanding RSUs and (ii) 57,159 Ordinary Shares
                                            issuable upon the exercise of options within 60 days.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in; text-align: left">(14)</TD><TD STYLE="text-align: justify">Consists of (i) 920,500
                                            Ordinary Shares vested pursuant to issued and outstanding RSUs and (ii) 57,159 Ordinary
                                            Shares issuable upon the exercise of options within 60 days.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>plan
of distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We are registering the Ordinary Shares previously
issued and issuable upon exercise of the Warrants to permit the resale of these Ordinary Shares by the holders thereof and holders of
the Ordinary Shares and Warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the
sale by the Selling Shareholders of the Ordinary Shares. All net proceeds from the sale of the Ordinary Shares covered by this prospectus
will go to the Selling Shareholders. However, we will receive cash proceeds equal to the total exercise price of the Warrants to the
extent that the Warrants are exercised using cash. We will bear all fees and expenses incident to our obligation to register the Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholders
may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time directly or through one
or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Shareholders
Selling Shareholders will be responsible for underwriting discounts or commissions or agent&rsquo;s commissions. The Resale Shares may
be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on
                                            any national securities exchange or quotation service on which the securities may be listed
                                            or quoted at the time of sale;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in transactions otherwise than on these exchanges or systems or in
    the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through the writing of options, whether such options are listed on
    an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer
    solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares
    as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer
    for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable
    exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">short sales;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sales pursuant to Rule 144;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">broker-dealers may agree with the selling securityholders to sell a
    specified number of such shares at a stipulated price per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods of sale; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Selling Shareholders
effect such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers
or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Shareholders or commissions from
purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or
commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the Ordinary Shares or otherwise, the Selling Shareholders may enter into hedging transactions
with broker-dealers, which may in turn engage in short sales of the Ordinary Shares in the course of hedging in positions they assume.
The Selling Shareholders may also sell Ordinary Shares short and Ordinary Shares covered by this prospectus to close out short positions
and to return borrowed shares in connection with such short sales. The Selling Shareholders may also loan or pledge Ordinary Shares to
broker-dealers that in turn may sell such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholders
may pledge or grant a security interest in some or all of the Warrants or Ordinary Shares owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the Ordinary Shares from time to time pursuant to this
prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if
necessary, the list of Selling Shareholders to include the pledgee, transferee or other successors in interest as Selling Shareholders
under this prospectus. The Selling Shareholders also may transfer and donate the Ordinary Shares in other circumstances in which case
the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholders
and any broker-dealer participating in the distribution of the Ordinary Shares may be deemed to be &ldquo;underwriters&rdquo; within
the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be
deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the Ordinary Shares
is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of Ordinary Shares being
offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other
terms constituting compensation from the Selling Shareholders and any discounts, commissions or concessions allowed or reallowed or paid
to broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the securities laws
of some states, the Ordinary Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in
some states the Ordinary Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption
from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that any Selling Shareholder will sell any or all of the Resale Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholders
and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934,
as amended, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit
the timing of purchases and sales of any of the Ordinary Shares by the Selling Shareholders and any other participating person. Regulation
M may also restrict the ability of any person engaged in the distribution of the Ordinary Shares to engage in market-making activities
with respect to the Ordinary Shares. All of the foregoing may affect the marketability of the Ordinary Shares and the ability of any
person or entity to engage in market-making activities with respect to the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay all expenses
of the registration of the Resale Shares, estimated to be $34,336.47 in total, including, without limitation, SEC filing fees and expenses
of compliance with state securities or &ldquo;blue sky&rdquo; laws; provided, however, that a Selling Shareholder will pay all underwriting
discounts and selling commissions, if any. We will indemnify the Selling Shareholders against liabilities, including some liabilities
under the Securities Act, in accordance with the Registration Rights Agreement, or the Selling Shareholders will be entitled to contribution.
We may be indemnified by the Selling Shareholders against civil liabilities, including liabilities under the Securities Act, that may
arise from any written information furnished to us by the Selling Shareholders specifically for use in this prospectus, in accordance
with the related Registration Rights Agreement, or we may be entitled to contribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once sold under the registration
statement, of which this prospectus forms a part, the Resale Shares will be freely tradable in the hands of persons other than our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any of
the proceeds from the sale of the Resale Shares by the Selling Shareholders pursuant to this prospectus. We may receive up to approximately
$4.7 million in aggregate gross proceeds from cash exercises of the Warrants, based on the applicable per share exercise price of the
Warrants. Any proceeds we receive from the exercise of the Warrants will be used to for working capital and general corporate purposes.
The Selling Shareholders will pay any agent&rsquo;s commissions and expenses they incur for brokerage, accounting, tax or legal services
or any other expenses that they incur in disposing of the Resale Shares. We will bear all other costs, fees and expenses incurred in
effecting the registration of the Shares covered by this prospectus. These may include, without limitation, all registration and filing
fees, SEC filing fees and expenses of compliance with state securities or &ldquo;blue sky&rdquo; laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &ldquo;Plan of Distribution&rdquo;
elsewhere in this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of
cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions,
including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors
our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay dividends only if,
upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able
to meet the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is
further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution
according to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements
relate is not more than six months prior to the date of distribution. In the event that we do not meet such earnings criteria, we may
seek the approval of a court in order to distribute a dividend. The court may approve our request if it is convinced that there is no
reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become
due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth our total liabilities and shareholders&rsquo; equity as of December 31, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma basis to give effect to the (i) issuance and sale of
    1,339,285 Ordinary Shares in the March Registered Direct Offering and (ii) issuance to Talniri of Warrants to purchase up to 220,000
    Ordinary Shares, at an exercise price of $2.25 per share, in February 2024; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma as adjusted basis to give effect to the issuance of
    3,463,438 Warrant Shares upon exercise of the Warrants at exercise prices between $1.28 and $2.25 per share, for aggregate gross
    proceeds of approximately 4.7 million, assuming such Warrants are exercised for cash.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this table
in conjunction with the sections titled &ldquo;Item 5. Operating and Financial Review and Prospects&rdquo; and our financial statements
and related notes included in our&nbsp;Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on
March 25, 2024, incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As
                                            of<BR> December&nbsp;31,<BR>
                                            2023<BR>
                                            Actual</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pro
                                            Forma<BR>
 As of<BR> December&nbsp;31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2023<BR>
                                            As&nbsp;Adjusted</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,041</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,690</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11,404</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Financials liability at Fair Value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shareholders&rsquo; equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share capital and additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,521</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,280</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,280</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total shareholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,548</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,674</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The above discussion and
table are based on 15,652,176 Ordinary Shares outstanding as of December 31, 2023, and excludes the following as of such date: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">542,800
                                            Ordinary Shares issuable upon the exercise of options to directors, employees and consultants
                                            under our equity incentive plan, outstanding as of such date, with exercise prices ranging
                                            between NIS 0.37 (approximately $0.11) to NIS 0.97 (approximately $0.29) per share, 29,400
                                            Ordinary Shares issuable upon the exercise of options to consultants under our equity incentive
                                            plan, outstanding as of such date, with exercise price of $3.08 and 80,000 Ordinary Shares
                                            issuable upon the exercise of options to consultants under our equity incentive plan, outstanding
                                            as of such date, with an exercise price of $1.002 (approximately $0.28); 434,373 of the total
                                            options were vested as of such date;</FONT> </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">452,573 RSU, granted to directors, employees, and consultants under
our equity incentive plan, none of which were vested as of such date;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">84,139 Ordinary Shares reserved for future issuance under our equity
    incentive plan;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">169,016 Ordinary Shares issuable upon the exercise of warrants issued
    to InSense Medical Pty Ltd. in connection with a certain termination agreement, with an exercise price of $5.50 per Ordinary Share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">795,832 Ordinary Shares issuable upon the exercise of warrants issued
    in connection with certain SAFEs&nbsp;and an additional 3,247 Ordinary Shares issuable upon the exercise of warrants issued to promoters
    in connection with such SAFEs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">353,750 Ordinary Shares issuable upon the exercise of warrants issued
    in connection with a certain convertible loan, and an additional 13,340 Ordinary Shares issuable upon the exercise of warrants issued
    to promoters in connection with such convertible loan agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">145,455 Ordinary Shares issuable upon the exercise of warrants issued
    to Aegis Capital Corp., who acted as the underwriter in connection with our IPO, at an exercise price of $6.875 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,640,455 Ordinary Shares issuable upon the exercise of warrants issued
    to investors in connection with our IPO Warrants at an exercise price of $5.50 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are the estimated
expenses of the issuance and distribution of the securities being registered under the registration statement of which this prospectus
forms a part, all of which will be paid by us. With the exception of the SEC registration fee, all amounts are estimates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,336.47</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Transfer agent fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Printer fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34,336.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_012"></A>LEGAL
MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters with
respect to the legality of the Resale Shares offered by this prospectus will be passed upon for us by Sullivan &amp; Worcester Tel Aviv
(Har-Even &amp; Co.), Tel Aviv, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_013"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023, incorporated by reference
into this prospectus and the registration statement have been so incorporated in reliance on the report of Ziv
Haft, a member firm of BDO, an independent registered public accounting firm, incorporated herein by reference, given on the
authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory
paragraph regarding the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>WHERE YOU CAN FIND ADDITIONAL
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form F-1, including relevant exhibits and schedules under the Securities Act with respect to Resale Shares
to be sold in this offering. This prospectus, which constitutes a part of the registration statement, does not contain all of the information
contained in the registration statement. You should read the registration statement on Form F-1 and its exhibits and schedules for further
information with respect to us and the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli company
and are a &ldquo;foreign private issuer&rdquo; as defined in Rule 3b-4 under the Exchange Act. As a foreign private issuer, we are exempt
from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are not required
under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as U.S. companies whose securities are registered under the Exchange Act. However, we file with the SEC, within 120 days after the end
of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited
by an independent registered public accounting firm, and submit to the SEC, on a Form 6-K, unaudited quarterly financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.inspira-technologies.com. The SEC also maintains a web site that contains information we file electronically with the SEC, which
you can access over the Internet at http://www.sec.gov. Information contained on, or that can be accessed through, our website and other
websites listed in this prospectus do not constitute a part of this prospectus. We have included these website addresses in this prospectus
solely as inactive textual references.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>ENFORCEABILITY OF CIVIL
LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in the
registration statement of which this prospectus forms a part, a substantial majority of whom reside outside of the United States, may
be difficult to obtain within the United States. Furthermore, because substantially all of our assets and a substantial of our directors
and officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors
and officers may not be collectible within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been informed by
our legal counsel in Israel, Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), that it may be difficult to assert U.S. securities
law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities
laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim,
it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of
applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also
be governed by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to specified time
limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions,
is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including
a monetary or compensatory judgment in a non-civil matter, provided that among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the judgment is obtained after due process before a court of competent
    jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently
    prevailing in Israel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the judgment is final and is not subject to any right
    of appeal;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the prevailing law of the foreign state in which the
    judgment was rendered allows for the enforcement of judgments of Israeli courts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">adequate service of process has been effected and
    the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the liabilities under the judgment are enforceable
    according to the laws of the State of Israel and the judgment and the enforcement of the civil liabilities set forth in the judgment
    is not contrary to the law or public policy in Israel nor likely to impair the security or sovereignty of Israel;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the judgment was not obtained by fraud and does not
    conflict with any other valid judgments in the same matter between the same parties;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">an action between the same parties in the same matter
    is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the judgment is enforceable according to the laws
    of Israel and according to the law of the foreign state in which the relief was granted.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a foreign judgment is
enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency
and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency
is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date
of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli
court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus interest at the annual statutory rate set by Israeli
regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information into this prospectus, which means that we can disclose important information to you by referring you
to other documents which we have filed with the SEC. We are incorporating by reference in this prospectus the documents listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Annual Report on&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea0202167-20f_inspira.htm">Form
    20-F</A></FONT>&nbsp;for the fiscal year ended December 31, 2023, filed with the SEC on March 25, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Reports on Form 6-K furnished on <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024000068/ea190978-6k_inspiratech.htm">January
    2, 2024</A> (with respect to the first and second paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024002057/ea191366-6k_inspiratech.htm">January
    9, 2024</A> (with respect to the first and second paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024007607/ea192468-6k_inspiratech.htm">January
    30, 2024</A> (with respect to the first three paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024011350/ea193169-6k_inspiratech.htm">February
    8, 2024</A> (with respect to the first two paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024013678/ea193761-6k_inspiratech.htm">February
    14, 2024</A> (with respect to the first, second and fourth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;),
    <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024015938/ea0200471-6k_inspiratech.htm">February 22, 2024</A> (with
    respect to the first three paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024017136/ea0200775-6k_inspiratech.htm">February
    27, 2024</A> (with respect to the first two paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024019279/ea0201110-6k_inspiratech.htm">March
    4, 2024</A> (with respect to the first, third, fourth and fifth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;),
    <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024019534/ea0201141-6k_inspiratech.htm">March 4, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024021039/ea0201435-6k_inspiratech.htm">March
    8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024021815/ea0201636-6k_inspiratec.htm">March 12, 2024</A>
    (with respect to the first, third and fourth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024023197/ea0201991-6k_inspira.htm">March
    18, 2024</A> (with respect to the first, second, fourth and fifth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;),
    <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024028248/ea0203004-6k_inspira.htm">April 1, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024029603/ea0203238-6k_inspira.htm">April 3, 2024</A> (with respect to the first two paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024031588/ea0203565-6k_inspira.htm">April 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024031743/ea0203633-6k_inspira.htm">April 10, 2024</A> (with respect to the first five paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024033583/ea0204064-6k_inspira.htm">April 17, 2024</A>
    (with respect to the first four paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024035965/ea0204624-6k_inspira.htm">April 24, 2024</A> (with
    respect to the first three paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024038793/ea0205143-6k_inspira.htm">May 2, 2024</A>; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The description of our securities contained in&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea020216701ex2-1_inspira.htm">Exhibit 2.1</A>&nbsp;to
    our Annual Report on <FONT STYLE="font-family: Times New Roman, Times, Serif">Form
    20-F</FONT> for the fiscal year ended December 31, 2023, filed with the SEC on March 25, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As you read the above documents,
you may find inconsistencies in information from one document to another. If you find inconsistencies between the documents and this
prospectus, you should rely on the statements made in the most recent document. All information appearing in this prospectus is qualified
in its entirety by the information and financial statements, including the notes thereto, contained in the documents incorporated by
reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide you without
charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits
to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests
to us at 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel, Tel: +972-996-64488; Attention: Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 4,416,916 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="width: 358px; height: 125px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION NOT REQUIRED
IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;6. Indemnification of Directors, Officers and Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Indemnification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
5759-2999, or the Companies Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify
an office holder against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either
pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision
authorizing such indemnification:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a financial liability imposed on him or her in favor of another person
    by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&rsquo;s
    award approved by a court;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, expended
    by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to
    conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such
    office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding
    (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial
    liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection
    with a monetary sanction;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, expended
    by the office holder or imposed on him or her by a court (1) in proceedings that the company institutes, or that another person institutes
    on the company&rsquo;s behalf, against him or her; (2) in a criminal proceeding of which he or she was acquitted; or (3) as a result
    of a conviction for a crime that does not require proof of criminal intent; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expenses incurred by an office holder in connection with an Administrative
    Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&rsquo; fees. An &ldquo;Administrative
    Procedure&rdquo; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative
    Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures
    subject to conditions) to the Securities Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also permits
a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability
imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and
amount or criterion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to events that in the opinion of the board of directors can be foreseen
    based on the company&rsquo;s activities at the time that the undertaking to indemnify is made; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in amount or criterion determined by the board of directors, at the
    time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into indemnification
agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the
office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities
are not covered by directors and officers insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exculpation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under the Companies Law, an Israeli company may not exculpate an office
holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance an office holder from his or her liability
to the company, in whole or in part, for damages caused to the company as a result of a breach of his or her duty of care (other than
in relation to distributions), but only if a provision authorizing such exculpation is included in its articles of association. Our amended
and restated articles of association provide that we may exculpate, in whole or in part, any office holder from liability to us for damages
caused to the company as a result of a breach of his or her duty of care, but prohibit an exculpation from liability arising from a company&rsquo;s
transaction in which our controlling shareholder or officer has a personal interest. Subject to the aforesaid limitations, under the indemnification
agreements, we exculpate and release our office holders from any and all liability to us related to any breach by them of their duty of
care to us to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would
provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty
of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable
basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was
carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive
an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the
fullest extent permitted or to be permitted by the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;7. Recent Sales of Unregistered
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are the sales
of all securities by the Company since May 2021, which were not registered under the Securities Act. The Company believes that each of
such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or
Regulation S under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January through March
2021, we entered into convertible loan agreements for the aggregate amount of $3,484,113. These convertible loan agreements had a maturity
date of May 31, 2021 and bear interest at the rate of 5.0% per year accrued quarterly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we offered an
extension with a maturity date of July 15, 2021 for the convertible loan agreements. The convertible loan agreements in the aggregate
amount of $3,053,920 were extended. We repaid $430,193 plus interest of 5% per year (approximately $7,000) to the investors who did not
agree to the extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, upon completion
of our initial public offering, the loan amount under the convertible loan agreements converted to Ordinary Shares at a conversion rate
equal to a discount of 20% from the per share price of our Ordinary Shares in this offering. Additionally, the investors received warrants
to purchase our Ordinary Shares with an exercise price equal to the public offering price in such offering with 50% warrant coverage
with a three year warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we issued warrants
to purchase 13,340 Ordinary Shares, exercisable upon our initial public offering for three years, to promoters in connection with the
convertible loan agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, upon completion
of our initial public offering, the loan amount under the convertible loan agreements converted to 707,489 Ordinary Shares at a conversion
rate equal to a discount of 20% from the per share price of our Ordinary Shares, which was $5.50. Additionally, the investors received
warrants to purchase 353,750 our Ordinary Shares with an exercise price equal to the public offering price of $5.50 per share in such
offering with 50% warrant coverage with a three year warrant.&nbsp; As of January 4, 2022, no warrants have been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, upon completion
of our initial public offering, the termination agreement with IML converted to 756,332 ordinary shares. Additionally, the investors
received warrants to purchase 169,016 our Ordinary Shares with an exercise price equal to $5.50. As of January 4, 2022, no warrants have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, upon completion
of our initial public offering, the investment amount under the SAFE converted to 1,406,416 of our Ordinary Shares. Additionally, the
investors received warrants to purchase 795,832 our Ordinary Shares with an exercise price equal to $5.50. As of January 4, 2022, no
warrants have been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 27, 2023, we entered into a purchase agreement, or the Purchase Agreement, with Armistice Capital LLC, or Armistice, in a registered
direct offering, pursuant to which we issued (i) an aggregate of 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, and
(ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less
$0.001 per Pre-Funded Warrant. In addition, pursuant to the Purchase Agreement, and in a concurrent private placement, we issued to Armistice
warrants, or the Armistice Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share, or
the Armistice Warrant Shares. The Armistice Warrants were exercisable immediately upon issuance and expire three and a half years following
their issuance. Each Pre-Funded Warrant was exercisable for one Ordinary Share at an exercise price of $0.001 per share. The Pre-Funded
Warrants were immediately exercisable and have been fully exercised. We received aggregate gross proceeds of $3.88 million in the registered
direct offering and concurrent private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">H.C.
Wainwright &amp; Co., LLC, or the Placement Agent, acted as the exclusive placement agent for the registered direct offering and
concurrent private placement. We paid the Placement Agent an aggregate fee equal to 7.0% of the gross proceeds of the offering, a
management fee of 1.0% of the gross proceeds of the offering, a non-accountable expenses allowance of $85,000 and a clearing fee of
$15,950. In addition, on December 28, 2023, we issued to the Placement Agent and its designees warrants to purchase up to 212,188 Ordinary
Shares, or the Placement Agent Warrants and such shares, the Placement Agent Warrant Shares. The Placement Agent Warrants were
substantially on the same terms as the Armistice Warrants, except that the Placement Agent Warrants have an exercise price of $1.60
per share. The Placement Agent Warrants were issued to four designees: Charles Worthman, Craig Schwabe, Michael Vasinkevich, and
Noam Rubinstein. Each of the designees is affiliated with the Placement Agent and has sole voting and dispositive power over the
securities held. The designees acquired the Placement Agent Warrants in the ordinary course of business and, at the time the
Placement Agent Warrants were acquired, had no agreement or understanding, directly or indirectly, with any person to distribute
such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with a consulting
agreement dated February 20, 2024, we issued to a service provider, Talniri Ltd., or Talniri, warrants to purchase up to 220,000 Ordinary
Shares, or the Talniri Warrants. The Talniri Warrants will become exercisable on May 20, 2024, or the Initial Exercise Date, at an exercise
price of $2.25 per share and will expire six months following the Initial Exercise Date, or on November 20, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;8. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibits:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 90%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>Exhibit&nbsp;Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-1_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (incorporated by reference to Exhibit 99.1 to Inspira
    Technologies Oxy B.H.N. Ltd.&rsquo;s Report of Foreign Issuer on Form 6-K (File No. 001-40303) filed with the SEC on December 20,
    2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021034372/ea143325ex4-1_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Representative&rsquo;s Warrant (incorporated by reference to Exhibit 4.1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Registration
    Statement on Form F-1 (File No. 333-253920) filed with the SEC on July 1, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-2_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agent Agreement (incorporated by reference to Exhibit 4.2 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Registration
    Statement Form F-1 (File No. 333-253920) filed with the SEC on July 1, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-4_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant (incorporated by reference to &nbsp;Exhibit 4.4 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Registration Statement
    FormF-1 (File No. 333-253920) filed with the SEC on July 1, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea020216701ex4-6_inspira.htm">Form of Amendment of Warrant Agreement by and between the Company and American Stock Transfer &amp; Trust Company, LLC, dated August 8, 2022 (incorporated by reference to &nbsp;Exhibit 4.6 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2023, dated March 24, 2024 (File No. 001-40303) filed with the SEC on December 27, 2023).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023098916/ea190727ex4-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Ordinary Warrant (incorporated by reference to &nbsp;Exhibit 4.1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Report of Foreign
    Issuer on Form 6-K (File No. 333-253920) filed with the SEC on December 27, 2023).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023098916/ea190727ex4-2_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Pre-Funded Warrant (incorporated by reference to &nbsp;Exhibit 4.1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Report of Foreign
    Issuer on Form 6-K (File No. 333-253920) filed with the SEC on December 27, 2023).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex4-7_inspira.htm">Form of Warrant by and between&nbsp;&nbsp;the Company and Talniri Ltd., dated February 20, 2024.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex4-8_inspira.htm">Form of Placement Agent Ordinary Share Warrant.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex5-1_inspira.htm">Opinion of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Israeli counsel to Inspira Technologies Oxy B.H.N. Ltd</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-1_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement. (incorporated by reference to &nbsp;Exhibit 10.1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Registration
    Statement on Form F-1 (File No. 333-253920) filed with the SEC on March 12, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021054754/ea149458ex10-2_inspiratech.htm">Inspira Technologies Oxy B.H.N. Ltd. (formerly known as: InSense Medical Ltd.) 2019 Equity Incentive Plan (amended on September 14, 2021), (incorporated by reference to Exhibit 10.2 to Post-Effective Amendment No. 1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s&nbsp;Registration Statement on Form F-1 (File No. 333-253920) filed with the SEC on October 27, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-2_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
    Technologies Oxy B.H.N. Ltd. Compensation Policy for Company&rsquo;s Executives (incorporated by reference to Exhibit 99.2 to Inspira
    Technologies Oxy B.H.N. Ltd.&rsquo;s Report of Foreign Private Issuer on Form 6-K (File No. 001-4030) filed with the SEC on December
    20, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-7_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Simple Agreement for Future Equity (incorporated by reference to &nbsp;Exhibit 10.7 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s
    Registration Statement on Form F-1 (File No. 333-253920) filed with the SEC on July 1, 2021)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021034372/ea143325ex10-8_inspiratec.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (incorporated by reference to Exhibit 10.8 to Inspira
    Technologies Oxy B.H.N. Ltd.&rsquo;s Registration Statement on Form F-1 (File No. 333-253920) filed with the SEC on July 1, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-8_inspiratech.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Convertible Loan Agreement (incorporated by reference to &nbsp;Exhibit 10.9 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s Registration
    Statement on Form F-1 (File No. 333-253920) filed with the SEC on July 1, 2021)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023098916/ea190727ex10-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement by and between the Company and H.C. Wainwright &amp; Co., LLC (incorporated by reference to Exhibit
    10.1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s &nbsp;Report of Foreign Issuer on Form 6-K (File No. 001-40303) filed with the
    SEC on December 27, 2023).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390024028248/ea020300401ex10-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement (incorporated by reference to &nbsp;Exhibit 10.1 to Inspira Technologies Oxy B.H.N. Ltd.&rsquo;s
    Report of Foreign Issuer on Form 6-K (File No. 001-40303) filed with the SEC on April 1, 2024).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex23-1_inspira.htm">Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex5-1_inspira.htm">Consent of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.) (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea0205650-f1_inspira.htm#a_017">Power
    of Attorney (included on signature page to the Registration Statement on Form F-1 filed on May 9, 2024).</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex-fee_inspira.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously filed.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Statement Schedules:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All financial statement schedules
have been omitted because either they are not required, are not applicable or the information required therein is otherwise set forth
in the Company&rsquo;s financial statements and related notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;9. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment
    to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To reflect in the prospectus any facts or events arising after the
    effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
    aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
    any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
    was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
    prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
    than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the
    effective registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To include any material information with respect to the plan of distribution
    not previously disclosed in the registration statement or any material change to such information in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining any liability under the Securities
    Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To remove from registration by means of a post-effective amendment
    any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To file a post-effective amendment to the registration statement to
    include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous
    offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided
    that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to
    this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current
    as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a
    post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act
    or Rule 3-19 of this chapter if such financial statements and information are contained in periodic reports filed with or furnished
    to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated
    by reference in the Form F-3.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining liability under the Securities
    Act of 1933 to any purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If the registrant is relying on Rule 430B:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">A.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each prospectus filed by the registrant pursuant to Rule 424(b)(3)
    shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the
    registration statement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">B.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5),
    or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i),
    (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed
    to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after
    effectiveness of the date of the first contract or sale of securities in the offering described in the prospectus. As provided in
    Rule 430B, for liability purposes of the issuer and any person that is at that date and underwriter, such date shall be deemed to
    be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus
    relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided,
    however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
    document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
    statement will, as to a purchaser with a time of contract sale prior to such effective date, supersede or modify any statement that
    was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
    prior to such effective date; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If the registrant is subject to Rule 430C, each prospectus filed pursuant
    to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B
    or other prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as
    of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus
    that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
    statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior
    to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the
    registration statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining liability of the registrant under
    the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes
    that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the
    underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means
    of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer
    or sell securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant
    relating to the offering required to be filed pursuant to Rule 424;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or
    on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The portion of any other free writing prospectus relating to the offering
    containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant;
    and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any other communication that is an offer in the offering made by the
    undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Pursuant to the requirements
of the Securities Act of&nbsp;1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-1 and has duly caused this Amendment No. 1 to Registration Statement on Form F-1 to be signed on its behalf by the
undersigned, thereunto duly authorized, in&nbsp;Ra&rsquo;anana, Israel on&nbsp;May 20, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap">/s/ Dagi Ben-Noon</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Pursuant to the requirements
of the Securities Act of 1933, this Amendment No. 1 to Registration Statement on Form F-1 has been signed by the following persons in
the capacities and on the dates indicated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi
    Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2024</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joe
    Hayon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, President and Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2024</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2024</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2024</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Amit</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2024</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*By:</FONT> </TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Dagi Ben-Noon</FONT> </TD>
    <TD STYLE="width: 60%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT> </TD>
    <TD> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attorney-in-fact</I></FONT> </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE OF AUTHORIZED
REPRESENTATIVE IN THE UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Pursuant to the Securities
Act of 1933, as amended, the undersigned, Puglisi &amp; Associates, the duly authorized representative in the United States of Inspira
Technologies Oxy B.H.N. Ltd., has signed this registration statement on May 20, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="margin-top: 0; margin-bottom: 0">Puglisi &amp; Associates &nbsp;</P>
                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                    <P STYLE="margin-top: 0; margin-bottom: 0">Authorized U.S. Representative</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Donald J. Puglisi</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Donald J. Puglisi</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Managing Director</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">II-8</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !] 68# 2(  A$! Q$!_\0
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MIM)1<O):_E?\"".)00.O7^7OFK 11T4?E5F+2=3D(,>G:A(N<KB!U/']XD#
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ML6"PG]H8;%8:JX>UP\:2A4]V233FH5H.]^2<5%N]G;F@[2@T>+ZCI4LY$RG
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M8! -<E32]NJ[^7WKH>WA8JBDX-Q23;@TIPMU5I-V7DI6ZJS1IPI&ZL]K/\I
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M@O\ =>*+1#_#+-&,\9V[AC'&#\IZGZU]!1\.0?[V?S'%<%I?P\O;/75U<WD
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MNR_9GO[;=L.522(%53@<9 YXP3SVJG?Z=-J,?B:PB=D6WQJHB4;A(LEJ',8
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M>9UPOIDUK*2QLXXY+5L\^5N5@N[CE3G\,$\8KPO6"%N)-N"KER.G0DD'\?\
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MI^?Y5M6V^2_,]3#;KY?J8I<)YI'5=Q4\D9&2!_G\:_J]^-W_  2K_8V\#_\
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MU9_',6MZ:?,#DM=7_AG1=*LY KRV4+Q,K/F?ML_\&Y?[#7[4_P"S9??MU?\
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M<JV+S'$Q_?XB=:HY8:G3YHQI8>F^5*4DS[7_ &&OV%_V@/\ @H1\=-+^"'P
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M;N?&<YFATFSC!(Z0$ \M7\<%I-;VU[I]S=D+:6VHZ=<WC' "VEO>P373$D$
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MXVNULK)Z--VZZZKN=>&AAG5B\13G4I*/*XQ<D^BC)\K3:7:ZN?O1_P %(O\
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MG_6YXN4XF>,I8J>+JN=>-HMZ.*NI59Q3ZJ+FHZ:732V=L>"4Q1.F?O3%\]^
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MN>&TEM(8(Q<2R@J'<R'._=DX(). ,<8_^M7'>/M7E-V]HT:F".-&=2Q_>Y)
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
